Delving into the Latest Updates on EG-017 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

+ [3]

Target

AR

Action

modulators

Mechanism

AR modulators(Androgen Receptor modulators)

Therapeutic Areas

Eye DiseasesNeoplasmsSkin and Musculoskeletal Diseases

Active Indication

XerophthalmiaAR Positive/ER Positive/HER2 Negative Breast CancerAdvanced breast cancer+ [1]

Inactive Indication

Urinary Incontinence, Stress

Originator Organization

Ningbo Xijian Medical Science & Technology Co. Ltd.

Active Organization

Changchun Genescience Pharmaceuticals Co., Ltd.

Inactive Organization

Ningbo Xijian Medical Science & Technology Co. Ltd.

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

主要目的以安慰剂为对照，评价EG017片治疗绝经后中老年女性压力性尿失禁（SUI）的有效性。次要目的适用于治疗期：1.以安慰剂为对照，在多个疗效评估时间点，以（除主要研究终点外的）其他多个疗效评价指标，评价EG017片治疗绝经后的中老年女性SUI的疗效；2.评估EG017片在绝经后中老年女性SUI患者中的药代动力学（PK）；3.评估EG017片用于绝经后中老年女性SUI患者治疗的安全性

[Translation]

Primary objective: To evaluate the effectiveness of EG017 tablets in the treatment of stress urinary incontinence (SUI) in postmenopausal middle-aged and elderly women, using placebo as a control. Secondary objectives: Applicable to the treatment period: 1. Using placebo as a control, at multiple efficacy evaluation time points, and using multiple efficacy evaluation indicators (except the primary study endpoint), to evaluate the efficacy of EG017 tablets in the treatment of SUI in postmenopausal middle-aged and elderly women; 2. To evaluate the pharmacokinetics (PK) of EG017 tablets in postmenopausal middle-aged and elderly women with SUI; 3. To evaluate the safety of EG017 tablets in the treatment of postmenopausal middle-aged and elderly women with SUI.

Start Date29 Jun 2023

Sponsor / Collaborator

Ningbo Xijian Medical Science & Technology Co. Ltd.

100 Clinical Results associated with EG-017

Login to view more data

100 Translational Medicine associated with EG-017

Login to view more data

100 Patents (Medical) associated with EG-017

Login to view more data

1

Literatures (Medical) associated with EG-017

Journal of Exercise Rehabilitation

Effects of two intensities of treadmill exercise on neuromuscular recovery after median nerve crush injury in Wistar rats

Article

Author: Souza, Renato A ; Santos, Ana Paula ; Ferreira, Marcílio Coelho ; Oliveira, Murilo X ; Machado, Thaís P G ; Souza, Josiane I

Considering the potential action of exercise on neuroplasticity and the need to adapt protocols to enhance functional recovery after nerve injury, this study evaluated the effects of two intensities of treadmill exercise on nervous and muscular tissues and functional recovery after nerve crush injury. Wistar rats were distributed into sedentary group (SED), and 10 m/min (EG10) and 17 m/min (EG17) exercise groups. The exercise started one week after the injury. Ten daily sessions were performed with a 2-day interval after the fifth day. The flexor digitorum muscle and two segments of the median nerve were analysed histomorphometrically by light microscopy and computer analysis. Function was evaluated by grasping test, in 3 moments. Approval number: 016/2013. In the proximal segments of the median nerve, the diameter of myelinated fibres and axon, the myelin sheath thickness and the ratio of axon diameter to fibre diameter (g ratio) were significantly larger (P<0.05) in the EG10. The number of myelinated fibres was lesser in the EG17 than the other groups (P<0.05). No difference in the number of myelinated fibres among groups was observed in the distal segments, but the SED presented significantly larger axon and fibre diameters than those that performed exercise. The EG10 presented greater area and diameter of muscle fibres (P<0.05) and functional improvement observed on the 21st day after injury (P<0.05) compared with the EG17 and SED. Continuous exercise at 10 m/min accentuates nerve regeneration, accelerating functional recovery and preventing muscle atrophy.

100 Deals associated with EG-017

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Xerophthalmia	Phase 2	China	Changchun Genescience Pharmaceuticals Co., Ltd.	20 Sep 2023
AR Positive/ER Positive/HER2 Negative Breast Cancer	Phase 1	China	Changchun Genescience Pharmaceuticals Co., Ltd.	16 May 2023
Advanced breast cancer	Phase 1	China	Changchun Genescience Pharmaceuticals Co., Ltd.	08 Mar 2023
Urinary Incontinence, Stress	Phase 1	China	Changchun Genescience Pharmaceuticals Co., Ltd.	06 Jan 2022
Urinary Incontinence, Stress	Phase 1	China	Ningbo Xijian Medical Science & Technology Co. Ltd.	06 Jan 2022
Urinary Incontinence, Stress	Preclinical	China	Ningbo Xijian Medical Science & Technology Co. Ltd.	06 Jan 2022
Urinary Incontinence, Stress	Preclinical	China	Changchun Genescience Pharmaceuticals Co., Ltd.	06 Jan 2022
Androgenetic Alopecia	Preclinical	China	Changchun Genescience Pharmaceuticals Co., Ltd.	-